NICE supports allowing technology assessment bodies to provide advice to drug industry

We read, with much astonishment, the article by Wise claiming that “selling” scientific advice procedures enables institutional capture by drug companies.1 The National Institute for Health and Care Excellence (NICE) strongly supports the development of processes for the provision of parallel scientific advice between the European Medicines Agency and Health Technology Assessment (HTA) bodies to the developers of medicinal products. The provision of scientific advice to …